Global RNA Interference (RNAi) Therapy Market Outlook 2018
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
The popularity of RNAi technology has been increasing in recent times as is has become a major component of basic research, and in drug discovery. Over the years this technology has become an integral part of the process of determining the functions of gene, in analyzing pathways, and in the validation of the target both in academia and in industry.
Since discovery, RNA interference is considered to be a turning point for molecular biology, it is most likely that this technology would grow in terms of its popularity and the significant research activity would be recorded in order to develop efficient and safe drug delivery mechanisms based on the RNAi therapy. Being a powerful tool for the study of functional genomics, this therapy provides enables the scientist to successfully silence any gene with artificial triggers of RNAi and utilizing the cellular machinery for efficient targeting of complementary transcripts.
There are specific strategic reasons for the pharmaceutical industry to take interest in developing RNAi-based therapeutics. With the existing product pipelines exhausting for the big pharma companies, they are currently looking into RNAi therapeutics as potential fields which would enable the pipelines to be filled. Additionally, these companies have identified RNAi therapeutics to have the capability to target those diseases which are considered to be “undruggable” by small-molecule compounds or biologics. Thus, by investing in RNAi therapeutics at an early stage, the pharma companies would be able to build a strong foothold and have a commanding position in the market once these RNAi-based drugs reached the market.
The RNAi therapy market, in the future years is likely to witness an increased level of activity in terms of RNAI technology development, specifically in the space of drug delivery. Though the main concept and clinical results behind RNAi are compelling, the pharma companies are still working towards identifying some new ideas which have great opportunity to grow. With human proof of concept demonstrated, it is most likely that the RNAi companies would reformulate new delivery technology and enjoy the benefits.
Global RNAi Therapy Report Highlights:
The popularity of RNAi technology has been increasing in recent times as is has become a major component of basic research, and in drug discovery. Over the years this technology has become an integral part of the process of determining the functions of gene, in analyzing pathways, and in the validation of the target both in academia and in industry.
Since discovery, RNA interference is considered to be a turning point for molecular biology, it is most likely that this technology would grow in terms of its popularity and the significant research activity would be recorded in order to develop efficient and safe drug delivery mechanisms based on the RNAi therapy. Being a powerful tool for the study of functional genomics, this therapy provides enables the scientist to successfully silence any gene with artificial triggers of RNAi and utilizing the cellular machinery for efficient targeting of complementary transcripts.
There are specific strategic reasons for the pharmaceutical industry to take interest in developing RNAi-based therapeutics. With the existing product pipelines exhausting for the big pharma companies, they are currently looking into RNAi therapeutics as potential fields which would enable the pipelines to be filled. Additionally, these companies have identified RNAi therapeutics to have the capability to target those diseases which are considered to be “undruggable” by small-molecule compounds or biologics. Thus, by investing in RNAi therapeutics at an early stage, the pharma companies would be able to build a strong foothold and have a commanding position in the market once these RNAi-based drugs reached the market.
The RNAi therapy market, in the future years is likely to witness an increased level of activity in terms of RNAI technology development, specifically in the space of drug delivery. Though the main concept and clinical results behind RNAi are compelling, the pharma companies are still working towards identifying some new ideas which have great opportunity to grow. With human proof of concept demonstrated, it is most likely that the RNAi companies would reformulate new delivery technology and enjoy the benefits.
Global RNAi Therapy Report Highlights:
- Introduction & Need Analysis of RNAi Therapy
- Benefits & Drug Delivery Mechanics Related to RNAi
- RNAi Therapy Market Insight
- Ongoing Clinical Trail/Pipeline for RNAi
- Detailed Insight on 151 RNAi Based Drugs in Clinical Trial
- Detailed Insight on 34 Suspended & No Development Reported RNAi Based Drugs in Clinical Trial
- Number of RNAi Based Drugs in Clinical Trials: 151
- Highest RNAi Clinical Trial in Preclinical Phase
- Oncology Dominating the RNAi Based Drugs Clinical Trial Process
- US Dominates RNAi Market & Clinical Trial Landscape
1. INTRODUCTION TO RNA INTERFERENCE (RNAI) THERAPY
1.1 Need for RNAi Therapy
1.2 RNAi Technologies
2. BENEFITS OF RNA INTERFERENCE (RNAI) THERAPY
3. RNA INTERFERENCE (RNAI) DRUG DELIVERY MECHANICS
3.1 Role of RNAi in Target Validation
3.2 Role of RNAi in Target Identification
4. GLOBAL RNA INTERFERENCE (RNAI) THERAPY MARKET OVERVIEW
4.1 Regional Markets
4.2 Ongoing RNAi Therapy Clinical Trial
5. GLOBAL RNA INTERFERENCE (RNAI) MARKET DYNAMICS
5.1 Favorable Market Drivers
5.2 Challenges to be Addressed
5.3 Future Growth Opportunities
6. RNAI CLINICAL PIPELINE BY PHASE, INDICATION & COUNTRY
6.1 Unknown Phase
6.2 Research
6.3 Preclinical
6.4 Phase-I
6.5 Phase I/II
6.6 Phase-II
6.7 Phase-III
7. SUSPENDED & DISCONTINUED RNAI PROFILES
7.1 No Development Reported
7.2 Discontinued
7.3 Suspended
8. COMPETITIVE LANDSCAPE
8.1 Arrowhead Research
8.2 Alnylam Pharmaceuticals
8.3 Benitec Biopharma
8.4 Dicerna Pharmaceuticals
8.5 InteRNA Technologies
8.6 Isis Pharmaceuticals
8.7 RXi Pharmaceuticals
8.8 Santaris Pharma
8.9 Silence Therapeutics
8.10 Tekmira Pharmaceuticals Corporation
1.1 Need for RNAi Therapy
1.2 RNAi Technologies
2. BENEFITS OF RNA INTERFERENCE (RNAI) THERAPY
3. RNA INTERFERENCE (RNAI) DRUG DELIVERY MECHANICS
3.1 Role of RNAi in Target Validation
3.2 Role of RNAi in Target Identification
4. GLOBAL RNA INTERFERENCE (RNAI) THERAPY MARKET OVERVIEW
4.1 Regional Markets
4.2 Ongoing RNAi Therapy Clinical Trial
5. GLOBAL RNA INTERFERENCE (RNAI) MARKET DYNAMICS
5.1 Favorable Market Drivers
5.2 Challenges to be Addressed
5.3 Future Growth Opportunities
6. RNAI CLINICAL PIPELINE BY PHASE, INDICATION & COUNTRY
6.1 Unknown Phase
6.2 Research
6.3 Preclinical
6.4 Phase-I
6.5 Phase I/II
6.6 Phase-II
6.7 Phase-III
7. SUSPENDED & DISCONTINUED RNAI PROFILES
7.1 No Development Reported
7.2 Discontinued
7.3 Suspended
8. COMPETITIVE LANDSCAPE
8.1 Arrowhead Research
8.2 Alnylam Pharmaceuticals
8.3 Benitec Biopharma
8.4 Dicerna Pharmaceuticals
8.5 InteRNA Technologies
8.6 Isis Pharmaceuticals
8.7 RXi Pharmaceuticals
8.8 Santaris Pharma
8.9 Silence Therapeutics
8.10 Tekmira Pharmaceuticals Corporation
LIST OF FIGURES
Figure 4-1: Global RNAi Therapy Market (US$ Billion), 2012-2018
Figure 4-2: RNAi Therapy Market by Region, 2013
Figure 4-3: Global RNAi Drug Clinical Pipeline by Phase (%), 2014
Figure 4-4: Global RNAi Drug Clinical Pipeline by Phase (Number of Drugs), 2014
Figure 4-5: Suspended & Discontinued RNAi Drug in Clinical Pipeline (%), 2014
Figure 4-6: Suspended & Discontinued RNAi Drug in Clinical Pipeline (Number of Drugs), 2014
Figure 4-7: Discontinued RNAi Drug Clinical Pipeline by Phase (%), 2014
Figure 4-8: Discontinued RNAi Drug Clinical Pipeline by Phase (Number of Drugs), 2014
Figure 4-9: Suspended RNAi Drug Clinical Pipeline by Phase (%), 2014
Figure 4-10: Suspended RNAi Drug Clinical Pipeline by Phase (Number of Drugs), 2014
Figure 4-1: Global RNAi Therapy Market (US$ Billion), 2012-2018
Figure 4-2: RNAi Therapy Market by Region, 2013
Figure 4-3: Global RNAi Drug Clinical Pipeline by Phase (%), 2014
Figure 4-4: Global RNAi Drug Clinical Pipeline by Phase (Number of Drugs), 2014
Figure 4-5: Suspended & Discontinued RNAi Drug in Clinical Pipeline (%), 2014
Figure 4-6: Suspended & Discontinued RNAi Drug in Clinical Pipeline (Number of Drugs), 2014
Figure 4-7: Discontinued RNAi Drug Clinical Pipeline by Phase (%), 2014
Figure 4-8: Discontinued RNAi Drug Clinical Pipeline by Phase (Number of Drugs), 2014
Figure 4-9: Suspended RNAi Drug Clinical Pipeline by Phase (%), 2014
Figure 4-10: Suspended RNAi Drug Clinical Pipeline by Phase (Number of Drugs), 2014
LIST OF TABLES
Table 8-1: Arrowhead Research Corporation RNAi Pipeline
Table 8-2: Alnylam Pharmaceuticals RNAi Pipeline
Table 8-3: Benitec Biopharma RNAi Pipeline
Table 8-4: Dicerna Pharmaceuticals RNAi Pipeline
Table 8-5: InteRNA Technologies RNAi Pipeline
Table 8-6: Isis Pharmaceuticals RNAi Pipeline
Table 8-7: RXi Pharmaceuticals Corporation RNAi Pipeline
Table 8-8: Santaris Pharma RNAi Pipeline
Table 8-9: Silence Therapeutics RNAi Pipeline
Table 8-10: Tekmira Pharmaceuticals RNAi Pipeline
FOLLOWING INFORMATION FOR EACH RNAI DRUG PROFILE IN COVERED IN MORE THAN 200 TABLES IN REPORT:
Active Indication
Phase of Development
Country/Region for Clinical Trial
Owner / Originator/ Licensee/Collaborator
Technology Provider
Chemical/Biological Class
Administrative Route
Drug Class
Table 8-1: Arrowhead Research Corporation RNAi Pipeline
Table 8-2: Alnylam Pharmaceuticals RNAi Pipeline
Table 8-3: Benitec Biopharma RNAi Pipeline
Table 8-4: Dicerna Pharmaceuticals RNAi Pipeline
Table 8-5: InteRNA Technologies RNAi Pipeline
Table 8-6: Isis Pharmaceuticals RNAi Pipeline
Table 8-7: RXi Pharmaceuticals Corporation RNAi Pipeline
Table 8-8: Santaris Pharma RNAi Pipeline
Table 8-9: Silence Therapeutics RNAi Pipeline
Table 8-10: Tekmira Pharmaceuticals RNAi Pipeline
FOLLOWING INFORMATION FOR EACH RNAI DRUG PROFILE IN COVERED IN MORE THAN 200 TABLES IN REPORT:
Active Indication
Phase of Development
Country/Region for Clinical Trial
Owner / Originator/ Licensee/Collaborator
Technology Provider
Chemical/Biological Class
Administrative Route
Drug Class
